Centers for Disease Control. National Diabetes Fact Sheet, United States, 2005. Available at: http://www.cdc.gov/diabetes/ pubs/pdf/ndfs_2005.pdf. Accessed September 5, 2006.
2.
Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990-1998. Diabetes Care. 2000;23:1278-1283.
Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
5.
American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Heart disease and stroke statistics— 2006 update. Circulation. 2006;113;85-151.
6.
Scott CLDiagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol.2003;92(suppl):35i-42i.
7.
Sobel BE, Frye R., Detre KMBurgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2003;107:636-642.
8.
Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329:977-986.
9.
Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group.Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
10.
Diabetes Control and Complications Trial Research Group.The relationship of glycemic exposure (HbA1C) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes Care. 1995 ;44:968-983.
11.
Skyler JSDiabetic complications: the importance of glucose control. Endocrinol Metab Clin North Am. 1996;25:243-254.
12.
Epidemiology of Diabetes Interventions and Complications Research Group.Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort . Diabetes Care.1999;22:99-111.
13.
Diabetes Control and ComplicationsTrial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med.2005; 353:2643-2653.
14.
Saydah SH, Fradkin J., Cowie CCPoor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA.2004;291:335-342.
15.
American Diabetes Association.Standards of medical care in diabetes. Diabetes Care. 2004;27(suppl 1):S15-S35.
16.
Monnier L., Lapinski H., Colette C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881-885.
17.
Nathan DNInitial management of glycemia in type 2 diabetes mellitus. N Engl J Med.2002;347:1342-1349.
18.
Brown JB, Nichols GAGlycemic burden of oral agent failure in type 2 diabetes [abstract]. Diabetes. 2003;52(suppl 1):A61-A62. Abstract 264-OR.
19.
American College of Endocrinology and American Association of Clinical Endocrinologists.Road map for the prevention and treatment of type 2 diabetes. Available at: http://www.aace.com/meetings/consensus/odimplementation. Accessed September 28, 2006.
20.
Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med.2003;348:383-393.
